Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors

Inclusion Criteria: * Age 18-70 years old, both men and women, and the survival period is more than 6 months. * At least one assessable focus, failure of previous multi-line treatment or stable condition after treatment. * Patients with melanoma confirmed by histopathology, patients with non-small cell lung cancer(squamous carcinoma) and head and neck squamous cell carcinoma. * The surgically removed pathological tissue can be used for immunohistochemical detection of target protein (paraffin section should be within 5 years), and the positive expression of target protein in line with pathological diagnosis (immunohistochemical staining + + or + + +). * Sufficient venous access for blood sampling and venous blood sampling, no contraindications for lymphocyte collection. * Routine blood examination: white blood cell count (WBC) ≥ 3 × 10\^9 / L, lymphocyte count (ly) ≥ 0.8 × 10\^9 / L, hemoglobin (HB) ≥ 90g / L, platelet (PLT) ≥ 80 × 10\^9/L. * Liver and kidney function: alanine aminotransferase and aspartate aminotransferase \< 3 ULN, total bilirubin (TBIL) \< 1.5 ULN, serum creatinine (SCR) \< 2 ULN. * The subjects voluntarily joined the study, signed the informed consent form, had good compliance and cooperated with the follow-up. Exclusion Criteria: * Active hepatitis B or hepatitis C virus, HIV infection, or other unhealed active infections. * Patients with second tumor. * Patients previously treated with car-t cells. * Requiring long-term use of immunosuppressants for any reason. * Any serious and uncontrolled systemic autoimmune disease or any unstable systemic disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, Crohn's disease and temporal arteritis. * Subjects with severe heart, lung, liver and kidney dysfunction or severe lung diseases. * Current systemic use of steroid cells (except for recent or current use of inhaled steroids). * Pregnant and lactating subjects. * Allergic to immunotherapy and related cells. * Subjects with a history of organ transplantation or waiting for organ transplantation. * After evaluation, the investigator considered that the subjects were unable or unwilling to comply with the requirements of the study protocol.